검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous NK cell therapy (Autologous NK cell therapy) Shenzhen Hornetcorn Bio-technology…·NK Cell Mediated Immunity 47 trials |
|---|---|
Overview Program | Autologous NK cell therapy |
Overview Company | Shenzhen Hornetcorn Bio-technology Company, LTD |
Overview Modality | CGT |
Overview Target | NK Cell Mediated Immunity |
Overview Indication | NK Cell Mediated Immunity; Endometriosis |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targeting both CAR antigen |
MoA Biomarker | biomarker of disease biology |
PK/PD Species | Mouse, vivo MPM xenograft |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, vivo MPM xenograft |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma.. To explore the feasibility and safety of natural killer (NK) cell therapy in HCC, we performed a prospective, open-label, phase I trial to evaluate the synergistic effect of locoregional high-dose autologous NK cel… |
Toxicology CRS | 83% |
Clinical PFS | 2 |
Clinical Result source | ClinicalTrials.gov NCT01729091 |
Clinical Data Tier / Score | A · 31 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous NK cell therapy (Autologous NK cell therapy) Shenzhen Hornetcorn Bio-technology…·NK Cell Mediated Immunity 47 trials |
|---|---|
Overview Program | Autologous NK cell therapy |
Overview Company | Shenzhen Hornetcorn Bio-technology Company, LTD |
Overview Modality | CGT |
Overview Target | NK Cell Mediated Immunity |
Overview Indication | NK Cell Mediated Immunity; Endometriosis |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targeting both CAR antigen |
MoA Biomarker | biomarker of disease biology |
PK/PD Species | Mouse, vivo MPM xenograft |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, vivo MPM xenograft |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma.. To explore the feasibility and safety of natural killer (NK) cell therapy in HCC, we performed a prospective, open-label, phase I trial to evaluate the synergistic effect of locoregional high-dose autologous NK cel… |
Toxicology CRS | 83% |
Clinical PFS | 2 |
Clinical Result source | ClinicalTrials.gov NCT01729091 |
Clinical Data Tier / Score | A · 31 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교